Cargando…

Organ response in patients with AL amyloidosis treated with NEOD001, an amyloid‐directed monoclonal antibody

Detalles Bibliográficos
Autores principales:	gertz, morie a., landau, heather j., weiss, brendan m.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2016
Materias:	E‐ONLY Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5132098/ https://www.ncbi.nlm.nih.gov/pubmed/27648922 http://dx.doi.org/10.1002/ajh.24563

Ejemplares similares

Role of Daratumumab in Cardiac AL Amyloidosis
por: Gertz, Morie A.
Publicado: (2022)

PB2161: BORTEZOMIB, POMALIDOMIDE, AND DEXAMETHASONE IS AN EFFECTIVE REGIMEN FOR PATIENTS WITH RELAPSE AND REFRACTORY AL AMYLOIDOSIS AND MONOCLONAL IMMUNOGLOBULIN DEPOSITION DISEASE
por: Liu, Yang, et al.
Publicado: (2023)

PB2025: MANAGEMENT AND PATIENT ESTIMATION OF AMYLOID LIGHT-CHAIN (AL) AMYLOIDOSIS IN PORTUGAL: RESULTS FROM A PHYSICIANS’ SURVEY
por: Santos, S., et al.
Publicado: (2022)

Thermal Stability Threshold for Amyloid Formation in Light Chain Amyloidosis
por: Poshusta, Tanya L., et al.
Publicado: (2013)

PB2097: CLINICAL IMPLICATION OF CYTOGENETIC ABERRATIONS IN NON-AL AMYLOIDOSIS MONOCLONAL GAMMOPATHY OF RENAL SIGNIFICANCE: A MULTI-CENTER CHINESE CASE SERIES
por: Liu, Yang, et al.
Publicado: (2023)

PB2008: CUTANEOUS HEMORRHAGIC SYNDROME IN PATIENTS WITH AL-AMYLOIDOSIS
por: Khyshova, V., et al.
Publicado: (2022)

PB2151: CLINICAL FEATURES AND OUTCOMES OF DIFFUSE PULMONARY LIGHT CHAIN AMYLOIDOSIS: A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS
por: Chakraborty, Rajshekhar, et al.
Publicado: (2023)

PB2135: TREATMENT PATTERNS IN PATIENTS WITH NEWLY DIAGNOSED AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018
por: Gertz, Morie A.
Publicado: (2018)

PB1989: LIGHT CHAIN AMYLOIDOSIS (AL): THE EXPERIENCE OF A TUNISIAN CENTER
por: Kallel, F., et al.
Publicado: (2022)

PB2154: THE IMPACT OF DISEASE SEVERITY ON THE CLINICAL AND ECONOMIC BURDEN OF AL AMYLOIDOSIS
por: D’souza, Anita, et al.
Publicado: (2023)

Peripheral Nervous, Hepatic, and Gastrointestinal Endpoints for AL Amyloidosis Clinical Trials: Report from the Amyloidosis Forum Multi-organ System Working Group
por: Mauermann, Michelle L., et al.
Publicado: (2023)

AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis
por: Manabe, Shun, et al.
Publicado: (2018)

Monoclonal antibodies and amyloid removal as a therapeutic strategy for cardiac amyloidosis
por: Emdin, Michele, et al.
Publicado: (2023)

PB1988: AL CARDIAC AMYLOIDOSIS: A CASE SERIES OF 13 PATIENTS AND LITERATURE REVIEW
por: Chadli, S., et al.
Publicado: (2022)

Importance of FISH genetics in light chain amyloidosis
por: Gertz, Morie A., et al.
Publicado: (2017)

Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2021
por: Hasib Sidiqi, M., et al.
Publicado: (2021)

PB2150: CARDIAC AMYLOID REACHING FOR EXTENDED SURVIVAL (CARES) TRIALS: 2 PLACEBO-CONTROLLED, DOUBLE-BLIND, RANDOMIZED, PHASE 3 TRIALS ASSESSING CAEL-101 IN PATIENTS WITH MAYO STAGES IIIA/IIIB AL AMYLOIDOSIS
por: Wechalekar, Ashutosh, et al.
Publicado: (2023)

PB2102: IMPACT OF AUTOLOGOUS STEM CELL TRASPLANTATION IN AL AMYLOIDOSIS. EXPERIENCE IN A SINGLE TERTIARY HOSPITAL
por: Alonso, Elena Alejo, et al.
Publicado: (2023)

Light chain (AL) amyloidosis: update on diagnosis and management
por: Rosenzweig, Michael, et al.
Publicado: (2011)

Light-chain cardiac amyloidosis: strategies to promote early diagnosis and cardiac response
por: Grogan, Martha, et al.
Publicado: (2017)

Advances in the treatment of hereditary transthyretin amyloidosis: A review
por: Gertz, Morie A., et al.
Publicado: (2019)

PB2002: OBSERVATIONAL PROSPECTIVE STUDY TO INVESTIGATE THE RELATIONSHIP BETWEEN DURATION OF TREATMENT AND RESPONSE IN PATIENTS WITH MULTIPLE MYELOMA OR AL AMYLOIDOSIS: THE DORIANT STUDY (NCT: 04659798)
por: Grande, M., et al.
Publicado: (2022)

Attention Deficit Hyperactivity Disorder‐Symptoms, Social Media Use Intensity, and Social Media Use Problems in Adolescents: Investigating Directionality
por: Boer, Maartje, et al.
Publicado: (2019)

Dissection of the amyloid formation pathway in AL amyloidosis
por: Kazman, Pamina, et al.
Publicado: (2021)

PB2155: B-CELL NON-HODGKIN’S LYMPHOMAS ASSOCIATED WITH AMYLOIDOSIS
por: Navrátilova, M., et al.
Publicado: (2022)

Monoclonal gammopathy of renal significance (MGRS)-related AL amyloidosis complicated by amyloid myopathy: a case report
por: Ono, Erina, et al.
Publicado: (2021)

PB2286: INFLUENCE OF ANTI-CD20 MONOCLONAL ANTIBODY THERAPY ON THE OUTCOME OF CORONAVIRUS INFECTION COVID-19 IN PATIENTS WITH LYMPHOPROLIFERATIVE DISEASES
por: Zotina, E., et al.
Publicado: (2022)

AL Amyloid Imaging and Therapy with a Monoclonal Antibody to a Cryptic Epitope on Amyloid Fibrils
por: Wall, Jonathan S., et al.
Publicado: (2012)

De Novo AL Amyloidosis in Renal Allograft and Anti-CD38 Monoclonal Antibody Treatment
por: Fotiou, Despina, et al.
Publicado: (2021)

OR14-001 – Tocilizumab in autoinflammation and AA amyloidosis
por: Lane, T, et al.
Publicado: (2013)

PB2089: ALGORITHM FOR SEVERE COVID-19 RISK STRATIFICATION DEPENDING MONOCLONAL ANTI-CD20 ANTIBODIES TREATMENT DURATION IN NON-HODGKIN LYMPHOMA PATIENTS.
por: Sychevskaya, K., et al.
Publicado: (2022)

The risk of recurrent VTE and major bleeding in a commercially‐insured population of cancer patients treated with anticoagulation
por: Khorana, Alok A., et al.
Publicado: (2018)

PB2319: ACQUIRED COAGULOPATHY: FACTOR X DEFICIENCY AT DIAGNOSIS OF MULTIPLE MYELOMA WITHOUT ASSOCIATED AMYLOIDOSIS
por: De La Torre De La Paz, M., et al.
Publicado: (2022)

PB2122: A PHASE 1/2 MULTI-CENTER, DOSE-FINDING STUDY INVESTIGATING THE SAFETY, TOLERABILITY, PK AND EFFICACY OF ZN-D5, A NOVEL BCL-2 INHIBITOR, IN PATIENTS WITH RELAPSED/REFRACTORY AL AMYLOIDOSIS
por: Kastritis, Efstathios, et al.
Publicado: (2023)

PB1762: A NEW MONOCLONAL ANTIBODY PROVIDES INSIGHTS ON NPM1 MUTANT SUBCELLULAR EXPRESSION, INTRACLONAL CELL DIFFERENTIATION AND MRD IN NPM1-MUTATED AML
por: Falini, Brunangelo, et al.
Publicado: (2023)

CD38 and Anti-CD38 Monoclonal Antibodies in AL Amyloidosis: Targeting Plasma Cells and beyond
por: Roccatello, Dario, et al.
Publicado: (2020)

Magnetic Resonance Elastography of Liver in Light Chain Amyloidosis
por: Venkatesh, Sudhakar K., et al.
Publicado: (2019)

Venetoclax for the treatment of translocation (11;14) AL amyloidosis
por: Sidiqi, M. Hasib, et al.
Publicado: (2020)

Diverse patterns of antibody variable gene repertoire disruption in patients with amyloid light chain (AL) amyloidosis
por: Chen, Elaine C., et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ffri31160cboma791kudvahc49